1 Guideline title

Hyperglycaemia: management of hyperglycaemia in people with acute coronary syndromes

1.1 Short title

Hyperglycaemia in acute coronary syndromes

2 The remit

The Department of Health has asked NICE: ‘to produce a short clinical guideline on the management of hyperglycaemia in acute coronary syndrome in patients both with and without diagnosed diabetes mellitus’.

3 Clinical need for the guideline

3.1 Epidemiology

a) Acute coronary syndromes (or ACS) encompass a spectrum of unstable coronary artery disease from unstable angina to transmural myocardial infarction. All forms begin with an inflamed and complicated fatty deposit (known as an atheromatous plaque) in a blood vessel, and blood clots forming on the plaque. The principles behind the presentation, investigation and management of these syndromes are similar, with important distinctions depending on the category of acute coronary syndrome.

b) Hyperglycaemia is common in patients when they are admitted to hospital with ACS. Recent studies found that approximately 65% of patients with acute myocardial infarction (heart attack) who were
not known to have diabetes had impaired glucose regulation when
given a glucose tolerance test.

c) For patients both with and without diabetes mellitus,
hyperglycaemia on admission is a powerful predictor of poorer
survival and increased risk of complications while in hospital.
Despite this, hyperglycaemia remains underappreciated as a risk
factor in acute coronary syndromes and it is frequently untreated.

d) Persistently elevated blood glucose levels during acute myocardial
infarction have been shown to be associated with increased in-
hospital mortality, and to a better predictor of outcome than
admission blood glucose.

3.2 **Current practice**

a) Currently, the management of hyperglycaemia in patients with
acute coronary syndromes is inconsistent across the UK, whether
or not patients have diagnosed diabetes.

b) The Joint British Societies’ guidelines on prevention of
cardiovascular disease in clinical practice recommend that:

- In people who present with an acute cardiovascular event,
fasting glucose should be measured at least once, or an oral
glucose tolerance test performed, during the hospital stay.

- Fasting glucose should be measured during the acute phase of
the illness. If there is evidence of impaired fasting glucose (more
than 6.0 mmol/litre but less than 7.0 mmol/litre) or an indication
of diabetes (more than 7.0 mmol/litre) fasting glucose should be
measured twice (or an oral glucose tolerance test performed
once) between 8 and 12 weeks after discharge from hospital.

c) The SIGN guidelines on acute coronary syndromes recommend
that patients with clinical myocardial infarction and diabetes or
marked hyperglycaemia (more than 11 mmol/litre) should be given
immediate intensive blood glucose control. This should be
continued for at least 24 hours. The European Society of Cardiology also recommends that patients with acute myocardial infarction and diabetes should be given tight glucometabolic control.

d) There is currently no relevant national guidance for England and Wales on the management of hyperglycaemia in patients with acute coronary syndromes.

4 The guideline

The guideline development process is described in detail on the NICE website (see section 6, ‘Further information’).

This scope defines what the guideline will (and will not) examine, and what the guideline developers will consider. The scope is based on the referral from the Department of Health.

The areas that will be addressed by the guideline are described in the following sections.

4.1 Population

4.1.1 Groups that will be covered

a) Adults (aged 18 years or older) with acute coronary syndromes and hyperglycaemia with a diagnosis of diabetes.

b) Adults with acute coronary syndromes and hyperglycaemia without a diagnosis of diabetes.

c) No sub groups were identified as needing specific consideration.

4.1.2 Groups that will not be covered

a) Children (aged 17 years or younger).

b) Adults with hyperglycaemia who do not have acute coronary syndromes.
c) Adults with acute coronary syndromes who do not have hyperglycaemia.

4.2 **Healthcare setting**

a) Secondary and tertiary care.

4.3 **Clinical management**

4.3.1 **Key clinical issues that will be covered**

a) Inpatient glucometabolic management (glucose, potassium and/or insulin) of hyperglycaemia in patients who have diagnosed diabetes mellitus.

b) Inpatient glucometabolic management (glucose, potassium and/or insulin) of hyperglycaemia in patients who do not have diagnosed diabetes mellitus.

c) Timing and frequency of tests for monitoring blood glucose in hospital.

d) Referral for subsequent investigation to confirm possible diabetes in patients without an existing diagnosis of diabetes.

e) Note that guideline recommendations will normally fall within licensed indications; exceptionally, and only if clearly supported by evidence, use outside a licensed indication may be recommended. The guideline will assume that prescribers will use a drug’s summary of product characteristics to inform decisions made with individual patients.

4.3.2 **Clinical issues that will not be covered**

a) Diagnosis of diabetes mellitus.

b) Management of diabetes mellitus.

c) Diagnosis of acute coronary syndromes.
d) Management of acute coronary syndromes.

e) Initial assessment and diagnosis of hyperglycaemia.

f) Types of medical devices used to measure hyperglycaemia.

g) Long-term management of hyperglycaemia and support beyond the acute phase.

4.4 Main outcomes

a) All-cause mortality.

b) Cardiovascular mortality.

c) Cardiovascular events associated with hyperglycaemia such as non-fatal reinfarction, heart failure and stroke.

d) Measures and control of blood glucose levels.

e) Health-related quality of life.

f) Adverse events associated with metabolic management of hyperglycaemia including hypoglycaemia and hypokalaemia.

g) Resource use and costs such as length of hospital stay.

4.5 Economic aspects

Developers will take into account both clinical and cost effectiveness when making recommendations involving a choice between alternative interventions. A review of the economic evidence will be conducted and analyses will be carried out as appropriate. The preferred unit of effectiveness is the quality-adjusted life year (QALY), and the costs considered will usually be only from an NHS and personal social services (PSS) perspective. Further detail on the methods can be found in 'The guidelines manual' (see 'Further information').

The key health economic question is the cost effectiveness of intensive glucose control compared with conventional glucose control in inpatients with
acute coronary syndromes and hyperglycaemia. The full economic analysis will be developed in conjunction with the clinical review and the Guideline Development Group.

4.6  Status

4.6.1  Scope
This is the consultation draft of the scope. The consultation dates are 6 July to 3 August 2010.

4.6.2  Timing
The development of the guideline recommendations will begin in September 2010.

5  Related NICE guidance

5.1  Published guidance


5.2 Guidance under development

NICE is currently developing the following related guidance (details available from the NICE website):


• Liraglutide for the treatment of type 2 diabetes. NICE technology appraisal guidance. Publication expected October 2010

• Ticagrelor for the treatment of acute coronary syndromes. NICE technology appraisal guidance. Publication expected July 2011.

• Long-acting exenatide for the second-line (dual therapy) or third-line (triple therapy) treatment of type 2 diabetes. NICE technology appraisal guidance. Publication date to be confirmed.

• Buccal insulin for the management of type 1 diabetes. NICE technology appraisal guidance. Publication date to be confirmed
6 Further information

Information on the guideline development process is provided in:

- ‘How NICE clinical guidelines are developed: an overview for stakeholders the public and the NHS’
- ‘The guidelines manual’.

These are available from the NICE website (www.nice.org.uk/GuidelinesManual). Information on the progress of the guideline will also be available from the NICE website (www.nice.org.uk).